Floatz logo

FILGRASTIM

Pancreatic Ductal Adenocarcinoma

Georgetown Universityprotein_peptidePhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

148 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 3B
Capecitabine
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 3B
Calcium folinate pentahydrate
Jonsson Comprehensive Cancer Center
Phase 3B
Durvalumab
Jonsson Comprehensive Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →